Clinical Trial Update: Phase II HDM-SPIRE Safety and Efficacy Study [Phase 2]

View source ↗

Summary

Phase II safety and efficacy study of HDM-SPIRE for rhinoconjunctivitis has completed, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• HDM-SPIRE (house dust mite sublingual immunotherapy extract)

Snippet

Sponsor: Circassia Limited | Conditions: Rhinoconjunctivitis | Phase 2 | Status: COMPLETED | Results posted: 2018-06-15